Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HNRNPA2B1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HNRNPA2B1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HNRNPA2B1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HNRNPA2B1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HNRNPA2B1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HNRNPA2B1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HNRNPA2B1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HNRNPA2B1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HNRNPA2B1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HNRNPA2B1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HNRNPA2B1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000640319 | Oral cavity | LP | RNA localization | 105/4623 | 201/18723 | 3.34e-17 | 5.36e-15 | 105 |
GO:000691318 | Oral cavity | LP | nucleocytoplasmic transport | 130/4623 | 301/18723 | 1.19e-12 | 9.77e-11 | 130 |
GO:005116918 | Oral cavity | LP | nuclear transport | 130/4623 | 301/18723 | 1.19e-12 | 9.77e-11 | 130 |
GO:005065715 | Oral cavity | LP | nucleic acid transport | 78/4623 | 163/18723 | 1.11e-10 | 6.44e-09 | 78 |
GO:005065815 | Oral cavity | LP | RNA transport | 78/4623 | 163/18723 | 1.11e-10 | 6.44e-09 | 78 |
GO:005123615 | Oral cavity | LP | establishment of RNA localization | 79/4623 | 166/18723 | 1.18e-10 | 6.81e-09 | 79 |
GO:001593115 | Oral cavity | LP | nucleobase-containing compound transport | 95/4623 | 222/18723 | 2.23e-09 | 9.98e-08 | 95 |
GO:005102814 | Oral cavity | LP | mRNA transport | 62/4623 | 130/18723 | 1.03e-08 | 3.90e-07 | 62 |
GO:005116818 | Oral cavity | LP | nuclear export | 68/4623 | 154/18723 | 9.55e-08 | 3.13e-06 | 68 |
GO:000072317 | Oral cavity | LP | telomere maintenance | 59/4623 | 131/18723 | 2.88e-07 | 8.56e-06 | 59 |
GO:007116611 | Oral cavity | LP | ribonucleoprotein complex localization | 38/4623 | 77/18723 | 2.47e-06 | 5.43e-05 | 38 |
GO:000640511 | Oral cavity | LP | RNA export from nucleus | 40/4623 | 84/18723 | 4.24e-06 | 8.71e-05 | 40 |
GO:007142611 | Oral cavity | LP | ribonucleoprotein complex export from nucleus | 37/4623 | 76/18723 | 5.02e-06 | 1.01e-04 | 37 |
GO:007189715 | Oral cavity | LP | DNA biosynthetic process | 71/4623 | 180/18723 | 8.04e-06 | 1.52e-04 | 71 |
GO:005105213 | Oral cavity | LP | regulation of DNA metabolic process | 125/4623 | 359/18723 | 9.43e-06 | 1.75e-04 | 125 |
GO:005105415 | Oral cavity | LP | positive regulation of DNA metabolic process | 77/4623 | 201/18723 | 1.20e-05 | 2.15e-04 | 77 |
GO:003150313 | Oral cavity | LP | protein-containing complex localization | 82/4623 | 220/18723 | 2.08e-05 | 3.44e-04 | 82 |
GO:200027818 | Oral cavity | LP | regulation of DNA biosynthetic process | 45/4623 | 106/18723 | 4.42e-05 | 6.30e-04 | 45 |
GO:003220415 | Oral cavity | LP | regulation of telomere maintenance | 36/4623 | 80/18723 | 5.80e-05 | 7.94e-04 | 36 |
GO:003304415 | Oral cavity | LP | regulation of chromosome organization | 70/4623 | 187/18723 | 6.89e-05 | 9.22e-04 | 70 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0501423 | Breast | IDC | Amyotrophic lateral sclerosis | 102/867 | 364/8465 | 1.29e-22 | 5.22e-21 | 3.91e-21 | 102 |
hsa0501433 | Breast | IDC | Amyotrophic lateral sclerosis | 102/867 | 364/8465 | 1.29e-22 | 5.22e-21 | 3.91e-21 | 102 |
hsa0501443 | Breast | DCIS | Amyotrophic lateral sclerosis | 101/846 | 364/8465 | 7.14e-23 | 2.88e-21 | 2.12e-21 | 101 |
hsa0501453 | Breast | DCIS | Amyotrophic lateral sclerosis | 101/846 | 364/8465 | 7.14e-23 | 2.88e-21 | 2.12e-21 | 101 |
hsa05014 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
hsa050141 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
hsa050142 | Colorectum | SER | Amyotrophic lateral sclerosis | 138/1580 | 364/8465 | 9.89e-19 | 2.99e-17 | 2.17e-17 | 138 |
hsa050143 | Colorectum | SER | Amyotrophic lateral sclerosis | 138/1580 | 364/8465 | 9.89e-19 | 2.99e-17 | 2.17e-17 | 138 |
hsa050144 | Colorectum | MSS | Amyotrophic lateral sclerosis | 156/1875 | 364/8465 | 1.43e-19 | 4.62e-18 | 2.83e-18 | 156 |
hsa050145 | Colorectum | MSS | Amyotrophic lateral sclerosis | 156/1875 | 364/8465 | 1.43e-19 | 4.62e-18 | 2.83e-18 | 156 |
hsa050146 | Colorectum | MSI-H | Amyotrophic lateral sclerosis | 95/797 | 364/8465 | 2.31e-21 | 1.50e-19 | 1.26e-19 | 95 |
hsa050147 | Colorectum | MSI-H | Amyotrophic lateral sclerosis | 95/797 | 364/8465 | 2.31e-21 | 1.50e-19 | 1.26e-19 | 95 |
hsa050148 | Colorectum | FAP | Amyotrophic lateral sclerosis | 91/1404 | 364/8465 | 1.84e-05 | 2.36e-04 | 1.44e-04 | 91 |
hsa050149 | Colorectum | FAP | Amyotrophic lateral sclerosis | 91/1404 | 364/8465 | 1.84e-05 | 2.36e-04 | 1.44e-04 | 91 |
hsa0501420 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
hsa05014110 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
hsa0501425 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
hsa0501435 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HNRNPA2B1 | SNV | Missense_Mutation | | c.951N>C | p.Lys317Asn | p.K317N | P22626 | protein_coding | deleterious(0.03) | benign(0.264) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HNRNPA2B1 | SNV | Missense_Mutation | | c.209N>T | p.Ser70Leu | p.S70L | P22626 | protein_coding | deleterious(0.03) | probably_damaging(0.975) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HNRNPA2B1 | SNV | Missense_Mutation | | c.124G>C | p.Glu42Gln | p.E42Q | P22626 | protein_coding | tolerated(0.13) | benign(0.192) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
HNRNPA2B1 | SNV | Missense_Mutation | | c.46N>A | p.Glu16Lys | p.E16K | P22626 | protein_coding | deleterious(0.01) | probably_damaging(0.932) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
HNRNPA2B1 | SNV | Missense_Mutation | novel | c.869A>G | p.Tyr290Cys | p.Y290C | P22626 | protein_coding | tolerated(0.17) | benign(0.339) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
HNRNPA2B1 | SNV | Missense_Mutation | novel | c.353G>A | p.Gly118Glu | p.G118E | P22626 | protein_coding | deleterious(0.01) | probably_damaging(0.954) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
HNRNPA2B1 | insertion | In_Frame_Ins | novel | c.356_357insGAACAAAAA | p.Ile119delinsMetAsnLysAsn | p.I119delinsMNKN | P22626 | protein_coding | | | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
HNRNPA2B1 | SNV | Missense_Mutation | | c.185N>T | p.Arg62Ile | p.R62I | P22626 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
HNRNPA2B1 | SNV | Missense_Mutation | | c.565N>C | p.Ser189Pro | p.S189P | P22626 | protein_coding | tolerated(0.08) | probably_damaging(0.927) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HNRNPA2B1 | SNV | Missense_Mutation | novel | c.389A>C | p.Asp130Ala | p.D130A | P22626 | protein_coding | deleterious(0) | possibly_damaging(0.467) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |